Home
    Disclaimer
    Fluoxymesterone molecular structure

    Fluoxymesterone Stats & Data

    Chemical Class Opioid
    Psychoactive Class Depressant

    Pharmacology

    DrugBank
    Half-life 9.2 hours State Solid

    Description

    An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.

    Mechanism of Action

    Fluoxymesterone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, fluoxymesterone binds to the androgen receptor. It produces retention of nitrogen, sodium, potassium, and phosphorus; increases protein anabolism; decreases amino acid catabolism and decreased urinary excretion of calcium. The antitumour activity of fluoxymesterone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production.

    Pharmacodynamics

    Fluoxymesterone is a synthetic androgen, or male hormone, similar to testosterone. Fluoxymesterone works by attaching itself to androgen receptors; this causes it to interact with the parts of the cell involved in the making of proteins. It may cause an increase in the synthesis of some proteins or a decrease in the synthesis of others. These proteins have a variety of effects, including blocking the growth of some types of breast cancer cells, stimulating cells that cause male sexual characteristics, and stimulating the production of red blood cells.

    Metabolism

    Presence of 17-alpha alkyl group reduces susceptibility to hepatic enzyme degradation, which slows metabolism and allows oral administration. Inactivation of testosterone occurs primarily in the liver

    Absorption

    Oral absorption is less than 44%.

    Toxicity

    Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.

    Indication

    In males, used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. In females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal.

    Protein Binding

    Very high (99%) with 80% to sex hormone binding globulin, 19% to albumin.

    Effect Profile

    Curated
    Opioid 5.1

    Strong euphoria with moderate itching/nausea, mild sedation

    Euphoria / Warmth×3
    9
    Analgesia×2
    0
    Sedation / Relaxation×1
    5
    Itching / Nausea×1
    6

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1d Half tolerance 21d Baseline ~35d
    ← Back to Fluoxymesterone